Truncated VWF Polypeptides for Factor VIII Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bleeding disorders, such as hemophilia A and von Willebrand disease, face challenges in maintaining the stability and half-life of Factor VIII due to its rapid clearance from plasma, particularly in conditions where von Willebrand Factor (VWF) is deficient or defective.
Innovation Solution
Development of modified truncated von Willebrand Factor polypeptides with enhanced binding affinity to Factor VIII, specifically through modifications in the D' and D3 domains, which form a complex to stabilize and prolong the half-life of Factor VIII in the plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If truncated VWF polypeptides are used to bind Factor VIII, then the half-life of Factor VIII is prolonged, but the binding affinity is insufficient compared to full-length VWF
Solution Approach 1:
The invention divides the full-length VWF into truncated polypeptides containing specific domains (D', D3, A1, A2, A3, C1, C2, CK) that retain FVIII binding capability. By segmenting VWF into functional domains, the patent achieves prolonged FVIII half-life while maintaining sufficient binding affinity through optimized domain composition.
Solution Approach 2:
The invention modifies the truncated VWF polypeptides through various parameters including amino acid substitutions (e.g., S764A, S764G, S766Y, V1083A), domain combinations, and molecular weight variations to enhance binding affinity to Factor VIII while maintaining the prolonged half-life effect.
2Reliability
If full-length VWF is used to stabilize Factor VIII, then binding affinity is high, but the complexity of the molecule increases production and purification difficulties
Solution Approach 1:
The invention extracts only the essential domains of VWF (truncated versions containing D', D3, A1, A2, A3, C1, C2, CK domains) that are necessary for FVIII binding and stabilization. This extraction removes unnecessary portions of the full-length VWF, reducing molecular complexity while preserving the critical binding function.
Solution Approach 2:
By segmenting full-length VWF into truncated polypeptides with specific domain compositions, the invention simplifies the molecular structure for easier production and purification while maintaining the essential FVIII binding capability through retained critical domains.
3Speed
If conventional FVIII replacement therapy is used, then immediate therapeutic effect is achieved, but frequent administration is required due to rapid clearance
Solution Approach 1:
The invention uses truncated VWF polypeptides as intermediary carrier molecules that bind to Factor VIII. This VWF-FVIII complex allows immediate therapeutic effect upon administration while the VWF component protects FVIII from rapid clearance, thereby extending its half-life and reducing administration frequency.
Data Source
Figure 1
Figure 2a~2d
Figure 3a~3d
AI summary
The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.